BRPI1014867A2 - anticorpos contra a tweak humana e usos dos mesmos. - Google Patents

anticorpos contra a tweak humana e usos dos mesmos.

Info

Publication number
BRPI1014867A2
BRPI1014867A2 BRPI1014867A BRPI1014867A BRPI1014867A2 BR PI1014867 A2 BRPI1014867 A2 BR PI1014867A2 BR PI1014867 A BRPI1014867 A BR PI1014867A BR PI1014867 A BRPI1014867 A BR PI1014867A BR PI1014867 A2 BRPI1014867 A2 BR PI1014867A2
Authority
BR
Brazil
Prior art keywords
antibodies against
against human
human tweak
tweak
antibodies
Prior art date
Application number
BRPI1014867A
Other languages
English (en)
Inventor
Hendrik Knoetgen
Jens Niewoehner
Monika Baehner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI1014867A2 publication Critical patent/BRPI1014867A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI1014867A 2009-04-02 2010-03-30 anticorpos contra a tweak humana e usos dos mesmos. BRPI1014867A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09004905 2009-04-02
PCT/EP2010/002009 WO2010115555A2 (en) 2009-04-02 2010-03-30 Antibodies against human tweak and uses thereof

Publications (1)

Publication Number Publication Date
BRPI1014867A2 true BRPI1014867A2 (pt) 2016-04-12

Family

ID=40673340

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014867A BRPI1014867A2 (pt) 2009-04-02 2010-03-30 anticorpos contra a tweak humana e usos dos mesmos.

Country Status (23)

Country Link
US (3) US8093006B2 (pt)
EP (2) EP2597104A1 (pt)
JP (1) JP5596777B2 (pt)
KR (1) KR101344611B1 (pt)
CN (1) CN102369219A (pt)
AR (1) AR076020A1 (pt)
AU (1) AU2010233997A1 (pt)
BR (1) BRPI1014867A2 (pt)
CA (1) CA2756245A1 (pt)
CL (1) CL2011002452A1 (pt)
CO (1) CO6362025A2 (pt)
CR (1) CR20110462A (pt)
EC (1) ECSP11011362A (pt)
IL (1) IL214355A0 (pt)
MA (1) MA33097B1 (pt)
MX (1) MX2011010117A (pt)
NZ (1) NZ594347A (pt)
PE (1) PE20120577A1 (pt)
RU (1) RU2011143903A (pt)
SG (2) SG10201404107SA (pt)
TW (1) TWI423815B (pt)
UA (1) UA105520C2 (pt)
WO (1) WO2010115555A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093006B2 (en) * 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
US9526846B2 (en) 2009-08-19 2016-12-27 Safety Syringes, Inc. Patient-contact activated needle stick safety device
WO2011097500A2 (en) 2010-02-04 2011-08-11 University Of Louisville Research Foundation, Inc. The tweak/fn14 system regulates skeletal muscle atrophy and regeneration
BR112013007293A2 (pt) 2010-10-05 2016-06-14 Hoffmann La Roche anticorpos contra a tweak de seres humanos e suas utilizações
US8609818B2 (en) 2011-03-10 2013-12-17 Omeros Corporation Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
KR101674784B1 (ko) 2012-04-05 2016-11-09 에프. 호프만-라 로슈 아게 인간 tweak 및 인간 il17에 대한 이중특이적 항체 및 이의 용도
JP2016000003A (ja) * 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトｔｗｅａｋ抗体
CN103399151A (zh) * 2013-06-24 2013-11-20 上海交通大学医学院附属瑞金医院 Cxcl8细胞因子检测试剂在制备甲状腺乳头状癌的诊断试剂中的应用
TWI843763B (zh) * 2018-10-31 2024-06-01 日商安斯泰來製藥股份有限公司 抗人類Fn14抗體
WO2025005938A1 (en) * 2023-06-26 2025-01-02 Memorial Sloan-Kettering Cancer Center Antibodies and antigen binding fragments thereof binding to chimeric receptors and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US7129061B1 (en) 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
CA2262756C (en) 1996-08-07 2012-06-12 Biogen, Inc. A tumor necrosis factor related ligand
JP2001513626A (ja) 1997-02-12 2001-09-04 アボツト・ラボラトリーズ 疾患の治療及び診断のために有用なｔｎｆファミリーのメンバー
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
AU749948B2 (en) 1997-10-10 2002-07-04 Genentech Inc. APO-3 ligand
EA004590B1 (ru) * 1999-01-15 2004-06-24 Байоджен, Инк. Способ блокировки развития, или снижения тяжести, или проявлений заболевания "трасплантат против хозяина"
JP2003521836A (ja) 1999-03-04 2003-07-15 ビジョン−サイエンシズ・インコーポレイテッド 個別に制御可能な電子シャッター回路を備えた画像センサユニットセル
GB9922069D0 (en) 1999-09-17 1999-11-17 Technolog Ltd Water distribution pressure control method and apparatus
WO2001030374A1 (en) 1999-10-22 2001-05-03 The University Of Pittsburgh Stem cell engraftment-enhancing cellular proteins and their uses
AU8028400A (en) 1999-10-22 2001-05-08 Scimed Life Systems, Inc. Guided injection device
CA2394015C (en) 1999-12-20 2013-11-05 Immunex Corporation Tweak receptor
US6943146B2 (en) 2000-05-08 2005-09-13 Biogen Idec Ma Inc. Method for promoting neovascularization
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
AU2003224950B2 (en) 2002-04-09 2006-09-14 Biogen Ma Inc. Methods for treating tweak-related conditions
EP1811838A4 (en) 2004-11-08 2009-07-22 Univ Maryland TWEAK AS A THERAPEUTIC TARGET FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM IN CONNECTION WITH CEREBRAL OEDEM AND CELL DEATH
US7939490B2 (en) 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
AU2006214179A1 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
WO2006088890A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating stroke
CN101171035A (zh) 2005-03-07 2008-04-30 健泰科生物技术公司 用于调控tweak和fn14活性的方法和组合物
WO2006122187A2 (en) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006130429A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
WO2006130374A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Tweak binding antibodies
US8093006B2 (en) * 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof

Also Published As

Publication number Publication date
AR076020A1 (es) 2011-05-11
NZ594347A (en) 2012-09-28
JP2012521771A (ja) 2012-09-20
CO6362025A2 (es) 2012-01-20
AU2010233997A1 (en) 2011-08-18
MX2011010117A (es) 2011-10-14
MA33097B1 (fr) 2012-03-01
CN102369219A (zh) 2012-03-07
EP2414398A2 (en) 2012-02-08
CR20110462A (es) 2011-09-21
US8093006B2 (en) 2012-01-10
TW201039847A (en) 2010-11-16
WO2010115555A3 (en) 2011-01-06
KR20110122868A (ko) 2011-11-11
CA2756245A1 (en) 2010-10-14
KR101344611B1 (ko) 2013-12-30
US20100255008A1 (en) 2010-10-07
WO2010115555A2 (en) 2010-10-14
US20120083015A1 (en) 2012-04-05
PE20120577A1 (es) 2012-05-23
US8852887B2 (en) 2014-10-07
SG10201404107SA (en) 2014-10-30
SG175005A1 (en) 2011-11-28
US8883976B2 (en) 2014-11-11
UA105520C2 (uk) 2014-05-26
ECSP11011362A (es) 2011-10-31
TWI423815B (zh) 2014-01-21
US20120207750A1 (en) 2012-08-16
RU2011143903A (ru) 2013-05-10
IL214355A0 (en) 2011-09-27
CL2011002452A1 (es) 2012-03-23
JP5596777B2 (ja) 2014-09-24
EP2597104A1 (en) 2013-05-29

Similar Documents

Publication Publication Date Title
SI2358756T2 (sl) Visokoafinitetna humana protitelesa proti PCSK9
BRPI1009455A2 (pt) anticorpos anti-c40 e usos dos mesmos
IL261257B (en) Humanized fc㚚šššššr mice
BRPI1011404A2 (pt) mutantes e usos dos mesmos
BRPI0919531A2 (pt) anticorpos contra il17 humana e usos dos mesmos
BRPI1008709A2 (pt) composições e usos das mesmas.
BRPI1013943A2 (pt) Composto cetais e usos dos mesmos.
DK2582728T3 (da) Humane antistof-lægemiddelkonjugater mod vævsfaktor
BR112013007499A2 (pt) piridazinonas - métodos de criação e usos
BRPI0912198A2 (pt) anticorpos anti-fn14 e usos dos mesmos
HRP20160737T1 (hr) Anti-her3-protutijela i njihove uporabe
BRPI1011710A2 (pt) lágrimas artificiais e usos trapêuticos
DK2475294T3 (da) Implanterbar sensor
BR112012003780A2 (pt) pregão semântico
BRPI1010644A2 (pt) inibidores da replicação do vírus da imunodeficiência humana
BRPI0924512A2 (pt) método e aparelho de fornecimento de execução de aplicativos seguros
BRPI1016117A8 (pt) derivados de isoxazol-isoxazol e isoxazol-isotiazol.
EP2207803A4 (en) CD9-SPECIFIC HUMAN ANTIBODIES
BR112012003844A2 (pt) vacinas de pttv e diagnóstico
BR112012010242A2 (pt) derivados de heteroarilpiperidina e heteroarilpiperazina
BRPI1007811A2 (pt) nacela de turborreator, e, turborreator
HRP20181973T1 (hr) Poboljšana anti humana fraktalkinska protutijela i njihova uporaba
FI20096339L (fi) Liima-aine, menetelmä sen valmistamiseksi sekä sen käyttö
BR112013002544A2 (pt) seção de armario e armario
BRPI1016067A2 (pt) ésteres e seus usos.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]